Stock DNA
Pharmaceuticals & Biotechnology
EUR 294 Million ()
NA (Loss Making)
NA
0.00%
-0.14
-33.59%
3.44
Revenue and Profits:
Net Sales:
15 Million
(Quarterly Results - Jun 2025)
Net Profit:
-21 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
53.07%
0%
53.07%
6 Months
221.6%
0%
221.6%
1 Year
131.68%
0%
131.68%
2 Years
56.99%
0%
56.99%
3 Years
85.64%
0%
85.64%
4 Years
-47.04%
0%
-47.04%
5 Years
-84.04%
0%
-84.04%
Cellectis SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.10%
EBIT Growth (5y)
10.04%
EBIT to Interest (avg)
-8.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.45
Sales to Capital Employed (avg)
0.14
Tax Ratio
8.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.38
EV to EBIT
-3.67
EV to EBITDA
-5.95
EV to Capital Employed
-10.87
EV to Sales
3.50
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-63.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2018
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
14.70
10.10
45.54%
Operating Profit (PBDIT) excl Other Income
-5.70
-10.50
45.71%
Interest
1.80
1.80
Exceptional Items
-0.20
1.80
-111.11%
Consolidate Net Profit
-20.90
-17.20
-21.51%
Operating Profit Margin (Excl OI)
-683.60%
-1,499.70%
81.61%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 45.54% vs -15.13% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -21.51% vs -407.14% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
38.40
0.70
5,385.71%
Operating Profit (PBDIT) excl Other Income
-44.60
-81.50
45.28%
Interest
6.90
5.90
16.95%
Exceptional Items
10.80
-19.00
156.84%
Consolidate Net Profit
-34.00
-108.10
68.55%
Operating Profit Margin (Excl OI)
-1,641.20%
-141,226.50%
13,958.53%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 5,385.71% vs -96.15% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 68.55% vs -15.12% in Dec 2023
About Cellectis SA 
Cellectis SA
Pharmaceuticals & Biotechnology
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Company Coordinates 
Company Details
8, rue de la Croix Jarry , PARIS None : 75013
Registrar Details






